Etienne C Hirsch

List of Publications by Citations

292 papers	29,727 citations	89 h-index	165 g-index
301 ext. papers	32,123 ext. citations	6.9 avg, IF	6.82 L-index

#	Paper	IF	Citations
292	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. *Lancet Neurology, The*, **2009**, 8, 382-97	24.1	1326
291	The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. *Brain*, **1999**, 122 (Pt 8), 1437-48	11.2	1226
290	Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. *Nature*, **1988**, 334, 345-8	50.4	1055
289	Dopamine depletion impairs precursor cell proliferation in Parkinson disease. *Nature Neuroscience*, **2004**, 7, 726-35	25.5	734
288	Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. *Journal of Clinical Investigation*, **2009**, 119, 182-92	15.9	668
287	Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 7531-6	11.5	594
286	Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 2875-80	11.5	586
285	Missing pieces in the Parkinson's disease puzzle. *Nature Medicine*, **2010**, 16, 653-61	50.5	521
284	Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. *Neuroscience*, **1996**, 72, 355-63	3.9	485
283	Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. *Neuroscience Letters*, **1994**, 172, 151-4	3.3	475
282	Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. *Journal of Neurochemistry*, **1991**, 56, 446-51	6	444
281	Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 5976-80	11.5	426
280	Neuroinflammation in Parkinson's disease. *Parkinsonism and Related Disorders*, **2012**, 18 Suppl 1, S210-2	3.6	411
279	Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. *Nature Genetics*, **1995**, 10, 104-10	36.3	394
278	FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. *Journal of Neuroscience*, **1999**, 19, 3440-7	6.6	369
277	Glutathione peroxidase, glial cells and Parkinson's disease. *Neuroscience*, **1993**, 52, 1-6	3.9	363
276	JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 665-70	11.5	350

275	The role of glial reaction and inflammation in Parkinson's disease. *Annals of the New York Academy of Sciences*, **2003**, 991, 214-28	6.5	344
274	The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. *Brain*, **1999**, 122 (Pt 8), 1421-36	11.2	322
273	Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 18578-83	11.5	314
272	Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. *Human Molecular Genetics*, **2003**, 12, 517-26	5.6	310
271	Understanding Dopaminergic Cell Death Pathways in Parkinson Disease. *Neuron*, **2016**, 90, 675-91	13.9	307
270	Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. *Journal of Clinical Investigation*, **2010**, 120, 2745-54	15.9	301
269	Neuroinflammatory processes in Parkinson's disease. *Annals of Neurology*, **2003**, 53 Suppl 3, S49-58; discussion S58-60	9.4	298
268	Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. *Journal of Neurochemistry*, **2002**, 82, 615-24	6	291
267	Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. *Annals of Neurology*, **1998**, 44, S115-20	9.4	259
266	Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. *Journal of Neurochemistry*, **2003**, 84, 491-502	6	253
265	Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. *Human Molecular Genetics*, **1998**, 7, 913-8	5.6	249
264	Activation of the subventricular zone in multiple sclerosis: evidence for early glial progenitors. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 4694-9	11.5	248
263	Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states. *Neuroscience*, **1997**, 76, 335-43	3.9	241
262	Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. *NeuroReport*, **1999**, 10, 557-61	1.7	240
261	Novel pharmacological targets for the treatment of Parkinson's disease. *Nature Reviews Drug Discovery*, **2006**, 5, 845-54	64.1	229
260	Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. *Brain*, **1996**, 119 (Pt 5), 1717-27	11.2	225
259	Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. *Journal of Neuroscience*, **2001**, 21, 2247-55	6.6	222
258	Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. *Journal of Neurochemistry*, **2003**, 86, 1297-307	6	220

257	The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 3585-90	11.5	217
256	Dopaminergic and cholinergic lesions in progressive supranuclear palsy. *Annals of Neurology*, **1985**, 18, 523-9	9.4	208
255	Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. *Molecular Biology of the Cell*, **2006**, 17, 1652-63	3.5	203
254	The p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. *Human Molecular Genetics*, **2003**, 12, 1427-37	5.6	198
253	Pathogenesis of Parkinson's disease. *Movement Disorders*, **2013**, 28, 24-30	7	197
252	Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?. *Journal of Neurochemistry*, **1992**, 59, 1080-9	6	191
251	Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?. *Journal of Chemical Neuroanatomy*, **2000**, 20, 253-7	3.2	185
250	Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. *Journal of Neurochemistry*, **2003**, 86, 1142-8	6	181
249	Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease?. *Annals of Neurology*, **1990**, 27, 676-82	9.4	178
248	Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. *Journal of Clinical Investigation*, **2006**, 116, 1410-24	15.9	176
247	Behavioural disorders induced by external globus pallidus dysfunction in primates: I. Behavioural study. *Brain*, **2004**, 127, 2039-54	11.2	172
246	Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. *Journal of Comparative Neurology*, **1993**, 330, 15-31	3.4	169
245	Blood vessels change in the mesencephalon of patients with Parkinson's disease. *Lancet, The*, **1999**, 353, 981-2	40	167
244	Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 9603-7	11.5	167
243	Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. *Journal of Neurochemistry*, **2004**, 88, 63-9	6	162
242	Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. *Glia*, **2004**, 46, 402-9	9	160
241	Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 6632-7	11.5	159
240	The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. *Journal of Neurochemistry*, **2005**, 95, 930-9	6	158

239	Neuroinflammatory processes in Parkinson's disease. *Parkinsonism and Related Disorders*, **2005**, 11 Suppl 1, S9-S15	3.6	154
238	Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. *Journal of Neuroscience*, **2007**, 27, 7827-37	6.6	151
237	Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease. *Neuroscience*, **2000**, 97, 79-88	3.9	145
236	An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. *Neuroscience*, **1999**, 88, 1015-32	3.9	145
235	Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. *European Journal of Neuroscience*, **2000**, 12, 337-44	3.5	144
234	Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: an in situ hybridization study of cytochrome oxidase subunit I mRNA. *Journal of Neuroscience*, **1997**, 17, 765-73	6.6	139
233	Nuclear translocation of NF-kappaB in cholinergic neurons of patients with Alzheimer's disease. *NeuroReport*, **1997**, 8, 2849-52	1.7	138
232	Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits. *Journal of Neuroscience*, **2005**, 25, 1523-31	6.6	132
231	Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. *Journal of Neuroscience*, **2006**, 26, 2321-5	6.6	130
230	Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death?. *Neuroscience*, **1996**, 73, 979-87	3.9	130
229	Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study. *Neuroscience*, **1990**, 38, 245-53	3.9	130
228	The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. *Neuroscience*, **2003**, 121, 287-96	3.9	129
227	Biochemistry of Parkinson's disease 28 years later: a critical review. *Movement Disorders*, **1989**, 4 Suppl 1, S126-44	7	129
226	Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. *Journal of Neuroscience*, **2004**, 24, 7007-14	6.6	127
225	Dopaminergic neurons degenerate by apoptosis in Parkinson's disease. *Movement Disorders*, **1999**, 14, 383-5	7	127
224	Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. *Neuroscience*, **1995**, 68, 1189-98	3.9	127
223	Preservation of midbrain catecholaminergic neurons in very old human subjects. *Brain*, **2000**, 123 (Pt 2), 366-73	11.2	116
222	Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?. *Journal of Neurochemistry*, **2001**, 76, 1785-93	6	115

221	New striatal dopamine neurons in MPTP-treated macaques result from a phenotypic shift and not neurogenesis. *Brain*, **2006**, 129, 1194-200	11.2	113
220	A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. *Brain*, **2007**, 130, 2898-914	11.2	108
219	Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. *Scientific Reports*, **2013**, 3, 1393	4.9	107
218	Metabolic activity of the basal ganglia in parkinsonian syndromes in human and non-human primates: a cytochrome oxidase histochemistry study. *Neuroscience*, **1996**, 71, 903-12	3.9	103
217	Differences in tyrosine hydroxylase-like immunoreactivity characterize the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 303-7	11.5	102
216	Rescue of mesencephalic dopaminergic neurons in culture by low-level stimulation of voltage-gated sodium channels. *Journal of Neuroscience*, **2004**, 24, 5922-30	6.6	99
215	Why are nigral catecholaminergic neurons more vulnerable than other cells in Parkinson's disease?. *Annals of Neurology*, **1992**, 32 Suppl, S88-93	9.4	99
214	Neuronal vulnerability in Parkinson's disease. *Journal of Neural Transmission Supplementum*, **1997**, 50, 79-88		98
213	Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. *Acta Neuropathologica*, **1996**, 91, 566-72	14.3	97
212	The pallidosubthalamic projection: an anatomical substrate for nonmotor functions of the subthalamic nucleus in primates. *Movement Disorders*, **2005**, 20, 172-80	7	96
211	Behavioural disorders induced by external globus pallidus dysfunction in primates II. Anatomical study. *Brain*, **2004**, 127, 2055-70	11.2	94
210	Does oxidative stress participate in nerve cell death in Parkinson's disease?. *European Neurology*, **1993**, 33 Suppl 1, 52-9	2.1	94
209	Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease?. *Brain Research*, **1994**, 668, 62-70	3.7	94
208	Caspase-3 activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. *Movement Disorders*, **2001**, 16, 185-9	7	93
207	Normal and pathological gait: what we learn from Parkinson's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 979-85	5.5	92
206	Lack of up-regulation of ferritin is associated with sustained iron regulatory protein-1 binding activity in the substantia nigra of patients with Parkinson's disease. *Journal of Neurochemistry*, **2002**, 83, 320-30	6	92
205	Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients. *Journal of Comparative Neurology*, **2000**, 425, 121-9	3.4	89
204	Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP?. *Neuroscience*, **1993**, 56, 499-511	3.9	89

203	Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. *Experimental Neurology*, **1996**, 5, 121-8		86
202	Heterogeneous intracellular localization and expression of ataxin-3. *Neurobiology of Disease*, **1998**, 5, 335-47	7.5	84
201	Atypical parkinsonism in Guadeloupe: a common risk factor for two closely related phenotypes?. *Brain*, **2007**, 130, 816-27	11.2	83
200	Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. *Neurobiology of Aging*, **2007**, 28, 568-78	5.6	83
199	Metabolic effects of nigrostriatal denervation in basal ganglia. *Trends in Neurosciences*, **2000**, 23, S78-85	13.3	82
198	Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. *Brain Research*, **2003**, 984, 224-32	3.7	81
197	Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. *Neurobiology of Disease*, **2003**, 14, 218-28	7.5	79
196	Consequence of nigrostriatal denervation and L-dopa therapy on the expression of glutamic acid decarboxylase messenger RNA in the pallidum. *Neurology*, **1996**, 47, 219-24	6.5	79
195	Glial cell line-derived neurotrophic factor (GDNF) gene expression in the human brain: a post mortem in situ hybridization study with special reference to Parkinson's disease. *Journal of Neural Transmission*, **1996**, 103, 1043-52	4.3	76
194	Selective loss of cholinergic neurons in the ventral striatum of patients with Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*, **1989**, 86, 8580-4	11.5	76
193	Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian. *Journal of Neural Transmission*, **2005**, 112, 1237-48	4.3	75
192	Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model. *PLoS ONE*, **2013**, 8, e61700	3.7	73
191	Superoxide dismutase and Parkinson's disease. *Lancet, The*, **1990**, 335, 1035-6	40	73
190	Expression of glutamate receptors in the human and rat basal ganglia: effect of the dopaminergic denervation on AMPA receptor gene expression in the striatopallidal complex in Parkinson's disease and rat with 6-OHDA lesion. *Journal of Comparative Neurology*, **1996**, 368, 553-68	3.4	71
189	Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis. *Journal of Neuroscience*, **2008**, 28, 9575-84	6.6	70
188	Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. *Experimental Neurology*, **2002**, 177, 183-92	5.7	70
187	c-fos protein-like immunoreactivity: distribution in the human brain and over-expression in the hippocampus of patients with Alzheimer's disease. *Neuroscience*, **1992**, 46, 9-21	3.9	70
186	Consequences of nigrostriatal denervation on the gamma-aminobutyric acidic neurons of substantia nigra pars reticulata and superior colliculus in parkinsonian syndromes. *Neurology*, **1996**, 46, 802-9	6.5	69

185	Dopamine, tremor, and Parkinson's disease. *Lancet, The*, **1992**, 340, 125-6	40	69
184	Gait disorders in parkinsonian monkeys with pedunculopontine nucleus lesions: a tale of two systems. *Journal of Neuroscience*, **2013**, 33, 11986-93	6.6	67
183	Paraxanthine, the primary metabolite of caffeine, provides protection against dopaminergic cell death via stimulation of ryanodine receptor channels. *Molecular Pharmacology*, **2008**, 74, 980-9	4.3	67
182	Three-dimensional cartography of functional territories in the human striatopallidal complex by using calbindin immunoreactivity. *Journal of Comparative Neurology*, **2002**, 450, 122-34	3.4	67
181	Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. *Annals of Neurology*, **1999**, 46, 103-11	9.4	67
180	Tyrosine hydroxylase protein and messenger RNA in the dopaminergic nigral neurons of patients with Parkinson's disease. *Brain Research*, **1993**, 606, 341-5	3.7	67
179	Protection of midbrain dopaminergic neurons by the end-product of purine metabolism uric acid: potentiation by low-level depolarization. *Journal of Neurochemistry*, **2009**, 109, 1118-28	6	66
178	Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer's disease. *Neuroscience*, **1989**, 32, 701-14	3.9	66
177	Mesencephalic cholinergic nuclei in progressive supranuclear palsy. *Neurology*, **1991**, 41, 25-30	6.5	65
176	The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. *Molecular Pharmacology*, **2006**, 70, 30-40	4.3	64
175	Neuroprotection of midbrain dopamine neurons by nicotine is gated by cytoplasmic Ca2+. *FASEB Journal*, **2011**, 25, 2563-73	0.9	63
174	Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson's disease?. *Neurology*, **1996**, 46, 1262-9	6.5	63
173	Decreased TrkA gene expression in cholinergic neurons of the striatum and basal forebrain of patients with Alzheimer's disease. *Experimental Neurology*, **1997**, 145, 245-52	5.7	62
172	Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. *Molecular Neurobiology*, **1994**, 9, 135-42	6.2	62
171	Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study. *Proceedings of the National Academy of Sciences of the United States of America*, **1992**, 89, 9549-53	11.5	62
170	Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. *Journal of Neurochemistry*, **2008**, 107, 701-11	6	61
169	Behavioral consequences of bicuculline injection in the subthalamic nucleus and the zona incerta in rat. *Journal of Neuroscience*, **2002**, 22, 8711-9	6.6	61
168	Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease. *Movement Disorders*, **2021**, 36, 16-24	7	60

167	Striosomes and extrastriosomal matrix contain different amounts of immunoreactive choline acetyltransferase in the human striatum. *Neuroscience Letters*, **1989**, 96, 145-50	3.3	59
166	Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. *Neurology*, **1995**, 45, 127-34	6.5	58
165	Dopaminergic cell group A8 in the monkey: Anatomical organization and projections to the striatum **1999**, 414, 334-347		57
164	Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. *Journal of Neurochemistry*, **1993**, 61, 1024-34	6	57
163	The iron-binding protein lactoferrin protects vulnerable dopamine neurons from degeneration by preserving mitochondrial calcium homeostasis. *Molecular Pharmacology*, **2013**, 84, 888-98	4.3	56
162	Effects of nigrostriatal denervation and L-dopa therapy on the GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA. *European Journal of Neuroscience*, **1995**, 7, 1199-209	3.5	56
161	Metabolic activity of cerebellar and basal ganglia-thalamic neurons is reduced in parkinsonism. *Brain*, **2007**, 130, 265-75	11.2	55
160	Tremor-related activity of neurons in the 'motor' thalamus: changes in firing rate and pattern in the MPTP vervet model of parkinsonism. *European Journal of Neuroscience*, **2003**, 17, 2388-400	3.5	55
159	FADD: A link between TNF family receptors and caspases in Parkinson's disease. *Neurology*, **2002**, 58, 308-10	6.5	55
158	Distribution of manganese-dependent superoxide dismutase in the human brain. *Neuroscience*, **1994**, 61, 317-30	3.9	55
157	The neurotransmitter noradrenaline rescues septal cholinergic neurons in culture from degeneration caused by low-level oxidative stress. *Molecular Pharmacology*, **2005**, 67, 1882-91	4.3	54
156	Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset. *NeuroReport*, **1998**, 9, 1823-6	1.7	54
155	Flavaglines as potent anticancer and cytoprotective agents. *Journal of Medicinal Chemistry*, **2012**, 55, 10064-73	8.3	53
154	Selective vulnerability of pigmented dopaminergic neurons in Parkinson's disease. *Acta Neurologica Scandinavica*, **1989**, 126, 19-22	3.8	53
153	Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system. *Neuroscience*, **1994**, 62, 449-57	3.9	51
152	Stathmin: cellular localization of a major phosphoprotein in the adult rat and human CNS. *Journal of Comparative Neurology*, **1993**, 337, 655-68	3.4	51
151	Distribution of ataxin-7 in normal human brain and retina. *Brain*, **2000**, 123 Pt 12, 2519-30	11.2	50
150	Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. *FASEB Journal*, **2013**, 27, 3414-23	0.9	49

149	Nitric oxide, glial cells and neuronal degeneration in parkinsonism. *Trends in Pharmacological Sciences*, **2000**, 21, 163-5	13.2	49
148	GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. *Neuroscience*, **1993**, 56, 965-72	3.9	49
147	The Oxygen Paradox, the French Paradox, and age-related diseases. *GeroScience*, **2017**, 39, 499-550	8.9	48
146	Quantitative autoradiography of tyrosine hydroxylase immunoreactivity in the rat brain. *Journal of Neurochemistry*, **1991**, 57, 1212-22	6	48
145	Distribution of 125I-ferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. *Journal of Neurochemistry*, **1993**, 60, 2338-41	6	48
144	NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients. *Frontiers in Cellular Neuroscience*, **2015**, 9, 245	6.1	47
143	Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. *Experimental Neurology*, **2003**, 184, 561-4	5.7	47
142	Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex. *Neuroscience*, **1994**, 61, 755-64	3.9	47
141	Neuronal vulnerability in Parkinson's disease. *Parkinsonism and Related Disorders*, **2012**, 18 Suppl 1, S52-4	3.6	46
140	Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease. *Human Mutation*, **1998**, 11, 23-7	4.7	46
139	Parkin immunoreactivity in the brain of human and non-human primates: an immunohistochemical analysis in normal conditions and in Parkinsonian syndromes. *Journal of Comparative Neurology*, **2001**, 432, 184-96	3.4	46
138	Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats. *Experimental Neurology*, **2000**, 162, 215-24	5.7	46
137	Differential vulnerability of cholinergic projections to the mediodorsal nucleus of the thalamus in senile dementia of Alzheimer type and progressive supranuclear palsy. *Neuroscience*, **1991**, 41, 25-31	3.9	46
136	Effect of mitochondrial complex I inhibition on Fe-S cluster protein activity. *Biochemical and Biophysical Research Communications*, **2011**, 409, 241-6	3.4	44
135	trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study. *Neuroscience*, **1998**, 86, 813-26	3.9	44
134	LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats. *Synapse*, **2001**, 42, 40-7	2.4	44
133	Consequences of dopaminergic denervation on the metabolic activity of the cortical neurons projecting to the subthalamic nucleus in the rat. *Journal of Neuroscience*, **2002**, 22, 8762-70	6.6	44
132	Differential distribution of the normal and mutated forms of huntingtin in the human brain. *Annals of Neurology*, **1997**, 42, 712-9	9.4	43

131	Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia. *Journal of Neurochemistry*, **1999**, 73, 344-52	6	43
130	Glial cells and Parkinson's disease. *Journal of Neurology*, **2000**, 247 Suppl 2, II58-62	5.5	43
129	Mitochondrial free calcium levels (Rhod-2 fluorescence) and ultrastructural alterations in neuronally differentiated PC12 cells during ceramide-dependent cell death. *Journal of Comparative Neurology*, **2000**, 426, 297-315	3.4	42
128	Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. *Annals of Neurology*, **1994**, 36, 206-14	9.4	42
127	Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Techniques, Side Effects, and Postoperative Imaging. *Stereotactic and Functional Neurosurgery*, **2016**, 94, 307-319	1.6	41
126	The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. *Brain Research*, **1997**, 749, 170-4	3.7	41
125	Ipsilateral and contralateral subthalamic activity after unilateral dopaminergic lesion. *NeuroReport*, **2000**, 11, 3275-8	1.7	41
124	Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease. *Neurobiology of Disease*, **2002**, 10, 28-32	7.5	40
123	Role of activity-dependent mechanisms in the control of dopaminergic neuron survival. *Journal of Neurochemistry*, **2007**, 101, 289-97	6	39
122	Distribution of semaphorin IV in adult human brain. *Brain Research*, **1999**, 823, 67-79	3.7	39
121	Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys. *European Journal of Neuroscience*, **2003**, 18, 2082-6	3.5	38
120	Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice. *Brain Research*, **2001**, 890, 347-50	3.7	38
119	Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys. *Brain Research*, **1995**, 691, 115-24	3.7	38
118	Analysis of monocyte infiltration in MPTP mice reveals that microglial CX3CR1 protects against neurotoxic over-induction of monocyte-attracting CCL2 by astrocytes. *Journal of Neuroinflammation*, **2017**, 14, 60	10.1	37
117	Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. *Journal of Neurochemistry*, **2009**, 110, 1321-9	6	37
116	Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys. *Molecular Brain Research*, **1996**, 42, 149-55		37
115	Neuronal localization of copper-zinc superoxide dismutase protein and mRNA within the human hippocampus from control and Alzheimer's disease brains. *Free Radical Research Communications*, **1991**, 12-13 Pt 2, 571-80		37
114	Distribution and morphology of nigral axons projecting to the thalamus in primates. *Journal of Comparative Neurology*, **2002**, 447, 249-60	3.4	36

113	Progressive supranuclear palsy: loss of choline-acetyltransferase-like immunoreactive neurons in the pontine reticular formation. *Neurology*, **1991**, 41, 1593-7	6.5	36
112	Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion. *Journal of Neuroscience*, **2014**, 34, 9124-33	6.6	35
111	Preferential expression of superoxide dismutase messenger RNA in melanized neurons in human mesencephalon. *Neuroscience*, **1993**, 55, 167-75	3.9	35
110	Hepcidin attenuates amyloid beta-induced inflammatory and pro-oxidant responses in astrocytes and microglia. *Journal of Neurochemistry*, **2017**, 142, 140-152	6	34
109	New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy. *Journal of Neurochemistry*, **1996**, 67, 19-25	6	34
108	Substance P, neurokinins A and B, and synthetic tachykinin peptides protect mesencephalic dopaminergic neurons in culture via an activity-dependent mechanism. *Molecular Pharmacology*, **2005**, 68, 1214-24	4.3	34
107	Pedunculopontine Nucleus Region Deep Brain Stimulation in Parkinson Disease: Surgical Anatomy and Terminology. *Stereotactic and Functional Neurosurgery*, **2016**, 94, 298-306	1.6	33
106	Dysfunction of the subthalamic nucleus induces behavioral and movement disorders in monkeys. *Movement Disorders*, **2009**, 24, 1183-92	7	33
105	Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats. *Journal of Neurochemistry*, **2003**, 86, 1328-37	6	33
104	The inflammatory response in the Parkinson brain. *Clinical Neuroscience Research*, **2001**, 1, 434-443		33
103	Clinical and pathological features in hydrocarbon-induced parkinsonism. *Annals of Neurology*, **1996**, 40, 922-5	9.4	33
102	Impairment of context-adapted movement selection in a primate model of presymptomatic Parkinson's disease. *Brain*, **2003**, 126, 1392-408	11.2	32
101	Blood vessels and parkinsonism. *Frontiers in Bioscience - Landmark*, **2004**, 9, 277-82	2.8	32
100	Trk neurotrophin receptors in cholinergic neurons of patients with Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **1997**, 8, 1-8	2.6	31
99	Cloning of rat parkin cDNA and distribution of parkin in rat brain. *Journal of Neurochemistry*, **2000**, 74, 1773-6	6	31
98	Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. *Brain Research*, **1995**, 692, 233-43	3.7	31
97	Motor neuron disease, parkinsonism and dementia. Report of a case with diffuse Lewy body-like intracytoplasmic inclusions. *Acta Neuropathologica*, **1987**, 75, 104-8	14.3	31
96	Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease. *Journal of Neuroinflammation*, **2014**, 11, 86	10.1	30

95	Proliferation of microglial cells induced by 1-methyl-4-phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. *Journal of Neurochemistry*, **2005**, 95, 1069-77	6	30
94	Role of pontine nuclei damage in smooth pursuit impairment of progressive supranuclear palsy: a clinical-pathologic study. *Neurology*, **1994**, 44, 716-21	6.5	30
93	Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease. *Annals of Neurology*, **1995**, 37, 265-72	9.4	30
92	Glucocorticoid receptor in astrocytes regulates midbrain dopamine neurodegeneration through connexin hemichannel activity. *Cell Death and Differentiation*, **2019**, 26, 580-596	12.7	29
91	Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography. *Brain Research*, **1994**, 659, 1-9	3.7	29
90	Dysfunction of mitochondrial Lon protease and identification of oxidized protein in mouse brain following exposure to MPTP: Implications for Parkinson disease. *Free Radical Biology and Medicine*, **2017**, 108, 236-246	7.8	28
89	Alzheimer's disease: is the decrease of the cholinergic innervation of the hippocampus related to intrinsic hippocampal pathology?. *Neuroscience*, **1992**, 47, 843-51	3.9	28
88	Iron transport in Parkinson's disease. *Parkinsonism and Related Disorders*, **2009**, 15 Suppl 3, S209-11	3.6	27
87	Mechanism and consequences of nerve cell death in Parkinson's disease. *Journal of Neural Transmission Supplementum*, **1999**, 56, 127-37		27
86	Localization of copper-zinc superoxide dismutase mRNA in human hippocampus by in situ hybridization. *Neuroscience Letters*, **1989**, 105, 41-6	3.3	26
85	Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration. *Neurology*, **1990**, 40, 1739-43	6.5	26
84	Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease. *Experimental Neurology*, **2016**, 275 Pt 1, 209-19	5.7	25
83	Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism: II. Effects of reward preference. *European Journal of Neuroscience*, **2004**, 19, 437-46	3.5	25
82	Ultrastructural localization of parkin in the rat brainstem, thalamus and basal ganglia. *Journal of Neural Transmission*, **2004**, 111, 1209-18	4.3	25
81	Expression of tachykinin NK2 receptor mRNA in human brain. *Neuroscience Letters*, **2001**, 303, 25-8	3.3	25
80	Cellular quantification of tyrosine hydroxylase in the rat brain by immunoautoradiography. *Journal of Neurochemistry*, **1993**, 61, 617-26	6	24
79	Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. *Movement Disorders*, **2002**, 17, 1174-9	7	24
78	Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem. *Developmental Neuroscience*, **1993**, 15, 37-48	2.2	24

77	Microtopography of D1 dopaminergic binding sites in the human substantia nigra: an autoradiographic study. *Neuroscience*, **1990**, 37, 387-98	3.9	24
76	Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. *Journal of Neurochemistry*, **2003**, 86, 1369-78	6	23
75	Age-related changes of neuronal counts in the human pedunculopontine nucleus. *Neuroscience Letters*, **2000**, 288, 195-8	3.3	23
74	Tyrosine hydroxylase gene expression in human ventral mesencephalon: detection of tyrosine hydroxylase messenger RNA in neurites. *Journal of Neuroscience Research*, **1990**, 25, 569-75	4.4	23
73	The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons. *Journal of Neurochemistry*, **2017**, 142, 14-28	6	22
72	Choline acetyltransferase mRNA expression in the striatal neurons of patients with Alzheimer's disease. *Neuroscience Letters*, **1997**, 225, 169-72	3.3	22
71	Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity. *European Journal of Neuroscience*, **2004**, 19, 426-36	3.5	22
70	The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice. *Neuroscience*, **2000**, 99, 643-50	3.9	22
69	Effect of melatonin on sleep disorders in a monkey model of Parkinson's disease. *Sleep Medicine*, **2015**, 16, 1245-51	4.6	21
68	Internal pallidum and substantia nigra control different parts of the mesopontine reticular formation in primate. *Movement Disorders*, **2011**, 26, 1648-56	7	21
67	Compartmental ordering of cholinergic innervation in the mediodorsal nucleus of the thalamus in human brain. *Brain Research*, **1990**, 515, 117-25	3.7	21
66	Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. *Journal of the Neurological Sciences*, **2015**, 356, 129-36	3.2	20
65	Expression of catalytic trkB gene in the striatum and the basal forebrain of patients with Alzheimer's disease: an in situ hybridization study. *Neuroscience Letters*, **1997**, 221, 141-4	3.3	20
64	Donepezil induces a cholinergic sprouting in basocortical degeneration. *Journal of Neurochemistry*, **2007**, 102, 434-40	6	20
63	AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa. *European Journal of Neuroscience*, **2002**, 16, 2236-40	3.5	20
62	Striatal expression of substance P and methionin-enkephalin in genes in patients with Parkinson's disease. *Neuroscience Letters*, **1995**, 199, 220-4	3.3	20
61	Animal models in neurodegenerative diseases. *Journal of Neural Transmission Supplementum*, **2007**, 87-90		19
60	Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum. *Brain Research*, **1993**, 624, 281-5	3.7	19

59	Cholinergic neuronal loss in the globus pallidus of Alzheimer disease patients. *Neuroscience Letters*, **1991**, 123, 152-5	3.3	19
58	Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism. *Journal of Neurochemistry*, **2013**, 127, 782-92	6	18
57	KATP channel blockade protects midbrain dopamine neurons by repressing a glia-to-neuron signaling cascade that ultimately disrupts mitochondrial calcium homeostasis. *Journal of Neurochemistry*, **2010**, 114, 553-64	6	18
56	Is differential regulation of mitochondrial transcripts in Parkinson's disease related to apoptosis?. *Journal of Neurochemistry*, **1997**, 68, 2098-110	6	17
55	Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease. *Journal of Comparative Neurology*, **2000**, 419, 175-92	3.4	17
54	Xenon-mediated neuroprotection in response to sustained, low-level excitotoxic stress. *Cell Death Discovery*, **2016**, 2, 16018	6.9	17
53	Long-term outcome in neuroZika: When biological diagnosis matters. *Neurology*, **2019**, 92, e2406-e2420	6.5	16
52	Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: a post-mortem study in human control subjects. *Neurobiology of Disease*, **2006**, 23, 409-21	7.5	16
51	Experimental evidence for a toxic etiology of tropical parkinsonism. *Movement Disorders*, **2005**, 20, 118-9	7	16
50	Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. *Molecular and Chemical Neuropathology*, **1996**, 28, 219-23		16
49	Tumor necrosis factor-like weak inducer of apoptosis induces astrocyte proliferation through the activation of transforming-growth factor-β/epidermal growth factor receptor signaling pathway. *Molecular Pharmacology*, **2012**, 82, 948-57	4.3	15
48	Striatal expression of glutamic acid decarboxylase gene in Alzheimer's disease. *Journal of Neurochemistry*, **1998**, 71, 767-74	6	13
47	Monoclonal antibodies raised against Lewy bodies in brains from subjects with Parkinson's disease. *Brain Research*, **1985**, 345, 374-8	3.7	13
46	Parafascicular nucleus projection to the extrastriatal basal ganglia in monkeys. *NeuroReport*, **2006**, 17, 277-80	1.7	12
45	In situ hybridization of GAD mRNA in monkey and human brain: quantification at both regional and cellular levels. *Neuroscience Letters*, **1993**, 157, 57-61	3.3	12
44	Piperazine derivatives as iron chelators: a potential application in neurobiology. *BioMetals*, **2015**, 28, 1043-61	3.4	11
43	The sleep-modulating peptide orexin-B protects midbrain dopamine neurons from degeneration, alone or in cooperation with nicotine. *Molecular Pharmacology*, **2015**, 87, 525-32	4.3	11
42	Seven Solutions for Neuroprotection in Parkinson's Disease. *Movement Disorders*, **2021**, 36, 306-316	7	11

41	Gangliosides and parkinsonism. *Neurology*, **1993**, 43, 2132-4	6.5	10
40	Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques. *European Journal of Neuroscience*, **2015**, 41, 129-36	3.5	9
39	DAP12 and CD11b contribute to the microglial-induced death of dopaminergic neurons in vitro but not in vivo in the MPTP mouse model of Parkinson's disease. *Journal of Neuroinflammation*, **2013**, 10, 82	10.1	9
38	Quantitative evaluation of the human subventricular zone. *Brain*, **2012**, 135, e221, 1-4; author reply e222, 1-6	11.2	9
37	Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA. *Journal of Neurochemistry*, **2002**, 80, 466-76	6	9
36	Plasticity of afferent fibers to striatal neurons bearing D1 dopamine receptors in Parkinson's disease. *Movement Disorders*, **2001**, 16, 435-41	7	9
35	Expression of Trk isoforms in brain regions and in the striatum of patients with Alzheimer's disease. *Experimental Neurology*, **2000**, 165, 285-94	5.7	9
34	Regional and cellular presenilin 2 (STM2) gene expression in the human brain. *NeuroReport*, **1996**, 7, 2021-5	1.7	9
33	Loss of striatal high affinity NGF binding sites in progressive supranuclear palsy but not in Parkinson's disease. *Neuroscience Letters*, **1994**, 182, 59-62	3.3	9
32	S29434, a Quinone Reductase 2 Inhibitor: Main Biochemical and Cellular Characterization. *Molecular Pharmacology*, **2019**, 95, 269-285	4.3	9
31	Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Journal of Neurochemistry*, **2012**, 122, 1032-46	6	8
30	How to improve neuroprotection in Parkinson's disease?. *Parkinsonism and Related Disorders*, **2007**, 13 Suppl 3, S332-5	3.6	8
29	Dopaminergic neurons reduced to silence by oxidative stress: an early step in the death cascade in Parkinson's disease?. *Science Signaling*, **2006**, 2006, pe19	8.8	8
28	In search of innovative therapeutics for neuropsychiatric disorders: the case of neurodegenerative diseases. *Annales Pharmaceutiques Francaises*, **2015**, 73, 3-12	1.3	7
27	MFGE8 does not orchestrate clearance of apoptotic neurons in a mouse model of Parkinson's disease. *Neurobiology of Disease*, **2013**, 51, 192-201	7.5	7
26	[125I]EGF binding in basal ganglia of patients with Parkinson's disease and progressive supranuclear palsy and in MPTP-treated monkeys. *Experimental Neurology*, **1998**, 154, 146-56	5.7	7
25	Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. *European Journal of Neuroscience*, **2000**, 12, 4525-4535	3.5	7
24	Increased mRNA expression of cytochrome oxidase in dorsal raphe nucleus of depressive suicide victims. *Neuropsychiatric Disease and Treatment*, **2008**, 4, 413-6	3.1	6

23	Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. *European Journal of Neuroscience*, **2000**, 12, 4525-4535	3.5	6
22	Low affinity nerve growth factor receptor, adrenal transplant and Parkinson's disease. *Journal of the Neurological Sciences*, **1993**, 120, 33-7	3.2	6
21	Tyrosine hydroxylase-like immunoreactivity in senile plaques is not related to the density of tyrosine hydroxylase-positive fibers in patients with Alzheimer's disease. *Neuroscience Letters*, **1990** , 110, 210-5	3.3	6
20	Characterization of two antigens in parkinsonian Lewy bodies. *Brain Research*, **1988**, 441, 139-44	3.7	6
19	Granulocyte colony-stimulating factor is not protective against selective dopaminergic cell death in vitro. *Neuroscience Letters*, **2005**, 383, 44-8	3.3	5
18	CD95 (APO-1/Fas) and Parkinson's disease. *Annals of Neurology*, **1998**, 44, 425-6	9.4	4
17	Neuronal plasticity and Parkinson disease. *Molecular and Chemical Neuropathology*, **1995**, 24, 251-5		4
16	Autoradiographic study of [125I]epidermal growth factor-binding sites in the mesencephalon of control and parkinsonian brains post-mortem. *Brain Research*, **1993**, 628, 72-6	3.7	4
15	Brain somatostatin concentrations do not decrease in progressive supranuclear palsy. *Journal of Neurology, Neurosurgery and Psychiatry*, **1987**, 50, 1526-8	5.5	4
14	Adrenal transplant, dopaminergic neurons, and Parkinson's disease. *Annals of Neurology*, **1993**, 33, 662-3	9.4	3
13	Neuroprotection of dopamine neurons by xenon against low-level excitotoxic insults is not reproduced by other noble gases. *Journal of Neural Transmission*, **2020**, 127, 27-34	4.3	3
12	Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice. *Movement Disorders*, **2020**, 35, 1843-1853	7	2
11	Blood Vessels And Neurodegeneration In Parkinson□ Disease. *Advances in Behavioral Biology*, **2002**, 341-347		2
10	Inflammatory Changes and Apoptosis in Parkinson□ Disease. *Advances in Behavioral Biology*, **2002**, 259-263		2
9	Localization of D1a dopamine receptors on cell bodies and axonal endings in the substantia nigra pars reticulata of the rat. *Journal of Neural Transmission*, **2007**, 114, 1509-17	4.3	1
8	Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson□ disease		1
7	Cholinergic Systems in Alzheimer□ Disease, Parkinson□ Disease and Progressive Supranuclear Palsy. *Advances in Behavioral Biology*, **1990**, 427-444		1
6	Futures pistes th□apeutiques m□icamenteuses pour la maladie de Parkinson. *Bulletin De LpAcademie Nationale De Medecine*, **2012**, 196, 1369-1379	0.1	1

5 Dissociated mesencephalic cultures **2008**, 389-408

4 A tribute for Prof. Dr. Melvin D. Yahr, M.D. (1917-2004). *Journal of Neural Transmission*, **2004**, 111, 1205-8 4.3

3 Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. *Annals of Neurology*, **2000**, 47, 136-136 9.4

2 Anatomo-Chemical Organization of the Basal Ganglia Circuitry in the Normal and Parkinsonian States. *Advances in Behavioral Biology*, **2002**, 521-530

1 Localization and Density of Transferrin Binding Sites in the Nigrostriatal System of Control Subjects and Patients with Parkinson Disease. *Advances in Behavioral Biology*, **1995**, 239-244